FAT1 and acute myeloid leukemia: Compared to wild-type patients (n=94), FAT1 mutant patients (n=14) showed no significant differences in age, gender, survival status, performance status score, AML type (primary or secondary), ELN2022 risk stratification, and treatment regimen type (p > 0.05, Table 2).